Endogenous retroviral promoter exaptation in human cancer

Mobile DNA

Volumn 7, Issue 1, 2016, Pages 1-21

  Babaian, Artem ^a,b   Mager, Dixie L ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alternative promoter; Cancer; Endogenous retrovirus; Epigenetics; Exaptation; Gene regulation; Long terminal repeat; Retrotransposon; Transcription

Indexed keywords

CHIMERIC PROTEIN; FATTY ACID BINDING PROTEIN; LONG UNTRANSLATED RNA; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR MARKER; TYROSINE KINASE RECEPTOR; UNTRANSLATED RNA;

CHROMOSOME TRANSLOCATION; ENDOGENOUS RETROVIRUS; EPIGENETICS; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE REGULATORY NETWORK; GENE REPRESSION; GENETIC CODE; GENETIC REGULATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 85000766782     PISSN: None     EISSN: 17598753     Source Type: Journal    
DOI: 10.1186/s13100-016-0080-x     Document Type: Review

References (225)

1. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001;409(6822):860-921.
2. Jurka J, Kapitonov VV, Kohany O, Jurka MV. Repetitive Sequences in Complex Genomes: Structure and Evolution. Annu Rev Genomics Hum Genet. 2007;8(1):241-59.
3. Brosius J, Gould SJ. On "genomenclature": a comprehensive (and respectful) taxonomy for pseudogenes and other "junk DNA". Proc Natl Acad Sci. 1992;89(22):10706-10.
4. Gould SJ, Vrba ES. Exaptation-A Missing Term in the Science of Form. Paleobiology. 1982;8(1):4-15.
5. Feschotte C, Gilbert C. Endogenous viruses: insights into viral evolution and impact on host biology. Nat Rev Genet. 2012;13(4):283-96.
6. Rebollo R, Romanish MT, Mager DL. Transposable Elements: An Abundant and Natural Source of Regulatory Sequences for Host Genes. Annu Rev Genet. 2012;46:21-42.
7. Richardson SR, Doucet AJ, Kopera HC, Moldovan JB, Garcia-Pérez JL, Moran JV: The Influence of LINE-1 and SINE Retrotransposons on Mammalian Genomes. Microbiol Spectr 2015, 3(2):10.1128/microbiolspec.MDNA1123-0061-2014
8. Robbez-Masson L, Rowe H. Retrotransposons shape species-specific embryonic stem cell gene expression. Retrovirology. 2015;12(1):45.
9. Hancks DC, Kazazian HH. Roles for retrotransposon insertions in human disease. Mob DNA. 2016;7(1):1-28.
10. Gerdes P, Richardson SR, Mager DL, Faulkner GJ. Transposable elements in the mammalian embryo: pioneers surviving through stealth and service. Genome Biol. 2016;17(1):1-17.
11. Weiss RA. Human endogenous retroviruses: friend or foe? APMIS. 2016;124(1-2):4-10.
12. Elbarbary RA, Lucas BA, Maquat LE. Retrotransposons as regulators of gene expression. Science. 2016;351(6274):aac7247.
13. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, Kazazian Jr HH. Hot L1s account for the bulk of retrotransposition in the human population. PNAS. 2003;100(9):5280-5.
14. Chen J, Stenson P, Cooper D, Ferec C. A systematic analysis of LINE-1 endonuclease-dependent retrotranspositional events causing human genetic disease. Hum Genet. 2005;117(5):411-27.
15. Kaer K, Speek M. Retroelements in human disease. Gene. 2013;518(2):231-41.
16. Miki Y, Nishisho I, Horii A, Miyoshi Y, Utsunomiya J, Kinzler KW, Vogelstein B, Nakamura Y. Disruption of the APC gene by a retrotransposal insertion of L1 sequence in a colon cancer. Cancer Res. 1992;52(3):643-5.
17. Lee E, Iskow R, Yang L, Gokcumen O, Haseley P, Luquette LJ, Lohr JG, Harris CC, Ding L, Wilson RK, et al. Landscape of Somatic Retrotransposition in Human Cancers. Science. 2012;337(6097):967-71.
18. Solyom S, Ewing AD, Rahrmann EP, Doucet TT, Nelson HH, Burns MB, Harris RS, Sigmon DF, Casella A, Erlanger B, et al. Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res. 2012;22(12):2328-38.
19. Shukla R, Upton KR, Munoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, et al. Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell. 2013;153(1):101-11.
20. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, et al. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science. 2014;345(6196):1251343.
21. Rodic N, Steranka JP, Makohon-Moore A, Moyer A, Shen P, Sharma R, Kohutek ZA, Huang CR, Ahn D, Mita P, et al. Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nat Med. 2015;21(9):1060-4.
22. Ewing AD, Gacita A, Wood LD, Ma F, Xing D, Kim M-S, Manda SS, Abril G, Pereira G, Makohon-Moore A, et al. Widespread somatic L1 retrotransposition occurs early during gastrointestinal cancer evolution. Genome Res. 2015;25(10):1536-45.
23. Scott EC, Gardner EJ, Masood A, Chuang NT, Vertino PM, Devine SE. A hot L1 retrotransposon evades somatic repression and initiates human colorectal cancer. Genome Res. 2016;26(6):745-55.
24. Bannert N, Kurth R. The Evolutionary Dynamics of Human Endogenous Retroviral Families. Annu Rev Genomics Hum Genet. 2006;7(1):149-73.
25. Jern P, Coffin JM. Effects of Retroviruses on Host Genome Function. Annu Rev Genet. 2008;42(1):709-32.
26. Magiorkinis G, Blanco-Melo D, Belshaw R. The decline of human endogenous retroviruses: extinction and survival. Retrovirology. 2015;12(1):1-12.
27. Rosenberg N, Jolicoeur P. Retroviral pathogenesis. In: Coffin JM, Hughes SH, Varmus H, editors. Retroviruses. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1997. p. 475-586.
28. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A. Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene. 2008;27(3):404-8.
29. Fan H, Johnson C. Insertional Oncogenesis by Non-Acute Retroviruses: Implications for Gene Therapy. Viruses. 2011;3(4):398-422.
30. Hohn O, Hanke K, Bannert N. HERV-K(HML-2), the best preserved family of HERVs: endogenisation, expression and implications in health and disease. Front Oncol. 2013;3:246.
31. Chen T, Meng Z, Gan Y, Wang X, Xu F, Gu Y, Xu X, Tang J, Zhou H, Zhang X, et al. The viral oncogene Np9 acts as a critical molecular switch for co-activating beta-catenin, ERK, Akt and Notch1 and promoting the growth of human leukemia stem/progenitor cells. Leukemia. 2013;27(7):1469-78.
32. Downey RF, Sullivan FJ, Wang-Johanning F, Ambs S, Giles FJ, Glynn SA. Human endogenous retrovirus K and cancer: Innocent bystander or tumorigenic accomplice? Int J Cancer. 2015;137(6):1249-57.
33. Kassiotis G. Endogenous Retroviruses and the Development of Cancer. J Immunol. 2014;192(4):1343-9.
34. Gomez-del Arco P, Kashiwagi M, Jackson AF, Naito T, Zhang J, Liu F, Kee B, Vooijs M, Radtke F, Redondo JM, et al. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity. 2010;33(5):685-98.
35. Thorsen K, Schepeler T, Øster B, Rasmussen MH, Vang S, Wang K, Hansen KQ, Lamy P, Pedersen JS, Eller A, et al. Tumor-specific usage of alternative transcription start sites in colorectal cancer identified by genome-wide exon array analysis. BMC Genomics. 2011;12(1):1-14.
36. Muratani M, Deng N, Ooi WF, Lin SJ, Xing M, Xu C, Qamra A, Tay ST, Malik S, Wu J, et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements. Nat Commun. 2014;5:4361.
37. Nagarajan RP, Zhang B, Bell RJA, Johnson BE, Olshen AB, Sundaram V, Li D, Graham AE, Diaz A, Fouse SD, et al. Recurrent epimutations activate gene body promoters in primary glioblastoma. Genome Res. 2014;24(5):761-74.
38. Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EWP, Hu W, Scott SN, Shah RH, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. 2015;526(7573):453-7.
39. O'Connell MR, Sarkar S, Luthra GK, Okugawa Y, Toiyama Y, Gajjar AH, Qiu S, Goel A, Singh P. Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications. Scie Rep. 2015;5:14983.
40. Grassilli E, Pisano F, Cialdella A, Bonomo S, Missaglia C, Cerrito MG, Masiero L, Ianzano L, Giordano F, Cicirelli V, et al. A novel oncogenic BTK isoform is overexpressed in colon cancers and required for RAS-mediated transformation. Oncogene. 2016;35:4368-78.
41. Maeso I, Tena JJ. Favorable genomic environments for cis-regulatory evolution: A novel theoretical framework. Semin Cell Dev Biol. 2016;57:2-10.
42. Thompson Peter J, Macfarlan Todd S, Lorincz Matthew C. Long Terminal Repeats: From Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire. Mol Cell. 2016;62(5):766-76.
43. Blomberg J, Benachenhou F, Blikstad V, Sperber G, Mayer J. Classification and nomenclature of endogenous retroviral sequences (ERVs): Problems and recommendations. Gene. 2009;448(2):115-23.
44. Mager DL, Stoye JP: Mammalian Endogenous Retroviruses. Microbiol Spectr 2015, 3(1). doi: 10.1128/microbiolspec.MDNA3-0009-2014.
45. Belshaw R, Dawson ALA, Woolven-Allen J, Redding J, Burt A, Tristem M. Genomewide Screening Reveals High Levels of Insertional Polymorphism in the Human Endogenous Retrovirus Family HERV-K(HML2): Implications for Present-Day Activity. J Virol. 2005;79(19):12507-14.
46. Wildschutte JH, Williams ZH, Montesion M, Subramanian RP, Kidd JM, Coffin JM. Discovery of unfixed endogenous retrovirus insertions in diverse human populations. Proc Natl Acad Sci. 2016;113(16):E2326-34.
47. Maksakova IA, Romanish MT, Gagnier L, Dunn CA, van de Lagemaat LN, Mager DL. Retroviral Elements and Their Hosts: Insertional Mutagenesis in the Mouse Germ Line. PLoS Genet. 2006;2(1):e2.
48. Belshaw R, Watson J, Katzourakis A, Howe A, Woolven-Allen J, Burt A, Tristem M. Rate of Recombinational Deletion among Human Endogenous Retroviruses. J Virol. 2007;81(17):9437-42.
49. Gemmell P, Hein J, Katzourakis A. Phylogenetic Analysis Reveals That ERVs "Die Young" but HERV-H Is Unusually Conserved. PLoS Comput Biol. 2016;12(6):e1004964.
50. Hubley R, Finn RD, Clements J, Eddy SR, Jones TA, Bao W, Smit AFA, Wheeler TJ. The Dfam database of repetitive DNA families. Nucleic Acids Res. 2016;44(D1):D81-9.
51. Kunarso G, Chia NY, Jeyakani J, Hwang C, Lu X, Chan YS, Ng HH, Bourque G. Transposable elements have rewired the core regulatory network of human embryonic stem cells. Nat Genet. 2010;42(7):631-4.
52. Chuong EB, Elde NC, Feschotte C. Regulatory evolution of innate immunity through co-option of endogenous retroviruses. Science. 2016;351(6277):1083-7.
53. Wang T, Zeng J, Lowe CB, Sellers RG, Salama SR, Yang M, Burgess SM, Brachmann RK, Haussler D. Species-specific endogenous retroviruses shape the transcriptional network of the human tumor suppressor protein p53. Proc Natl Acad Sci. 2007;104(47):18613-8.
54. Jacques P-E, Jeyakani J, Bourque G. The Majority of Primate-Specific Regulatory Sequences Are Derived from Transposable Elements. PLoS Genet. 2013;9(5):e1003504.
55. Xie M, Hong C, Zhang B, Lowdon RF, Xing X, Li D, Zhou X, Lee HJ, Maire CL, Ligon KL, et al. DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet. 2013;45(7):836-41.
56. Kelley D, Rinn J. Transposable elements reveal a stem cell specific class of long noncoding RNAs. Genome Biol. 2012;13(11):R107.
57. Lu X, Sachs F, Ramsay L, Jacques PE, Goke J, Bourque G, Ng HH. The retrovirus HERVH is a long noncoding RNA required for human embryonic stem cell identity. Nat Struct Mol Biol. 2014;21(4):423-5.
58. Wang J, Xie G, Singh M, Ghanbarian AT, Rasko T, Szvetnik A, Cai H, Besser D, Prigione A, Fuchs NV, et al. Primate-specific endogenous retrovirus-driven transcription defines naive-like stem cells. Nature. 2014;516(7531):405-9.
59. Durruthy-Durruthy J, Sebastiano V, Wossidlo M, Cepeda D, Cui J, Grow EJ, Davila J, Mall M, Wong WH, Wysocka J, et al. The primate-specific noncoding RNA HPAT5 regulates pluripotency during human preimplantation development and nuclear reprogramming. Nat Genet. 2016;48:44-52.
60. Izsvák Z, Wang J, Singh M, Mager DL, Hurst LD. Pluripotency and the endogenous retrovirus HERVH: Conflict or serendipity? BioEssays. 2016;38(1):109-17.
61. Emera D, Wagner GP. Transposable element recruitments in the mammalian placenta: impacts and mechanisms. Brief Funct Genomics. 2012;11(4):267-76.
62. Feschotte C. Transposable elements and the evolution of regulatory networks. Nat Rev Genet. 2008;9(5):397-405.
63. Cohen CJ, Lock WM, Mager DL. Endogenous retroviral LTRs as promoters for human genes: a critical assessment. Gene. 2009;448(2):105-14.
64. Rayan NA, del Rosario RCH, Prabhakar S. Massive contribution of transposable elements to mammalian regulatory sequences. Semin Cell Dev Biol. 2016;57:51-6.
65. Friedli M, Trono D. The Developmental Control of Transposable Elements and the Evolution of Higher Species. Annu Rev Cell Dev Biol. 2015;31(1):429-51.
66. Nigumann P, Redik K, Matlik K, Speek M. Many human genes are transcribed from the antisense promoter of L1 retrotransposon. Genomics. 2002;79(5):628-34.
67. Mätlik K, Redik K, Speek M. L1 Antisense Promoter Drives Tissue-Specific Transcription of Human Genes. J Biomed Biotechnol. 2006;2006:71753.
68. Rebollo R, Farivar S, Mager DL. C-GATE - catalogue of genes affected by transposable elements. Mob DNA. 2012;3(1):9.
69. Criscione SW, Theodosakis N, Micevic G, Cornish TC, Burns KH, Neretti N, Rodić N. Genome-wide characterization of human L1 antisense promoter-driven transcripts. BMC Genomics. 2016;17(1):1-15.
70. Denli Ahmet M, Narvaiza I, Kerman Bilal E, Pena M, Benner C, Marchetto Maria CN, Diedrich Jolene K, Aslanian A, Ma J, Moresco James J, et al. Primate-Specific ORF0 Contributes to Retrotransposon-Mediated Diversity. Cell. 2015;163(3):583-93.
71. Szak ST, Pickeral OK, Makalowski W, Boguski MS, Landsman D, Boeke JD. Molecular archeology of L1 insertions in the human genome. Genome Biol. 2002;3(10):research0052. 0051-research0052.0018.
72. Khan H, Smit A, Boissinot S. Molecular evolution and tempo of amplification of human LINE-1 retrotransposons since the origin of primates. Genome Res. 2006;16(1):78-87.
73. Faulkner GJ, Kimura Y, Daub CO, Wani S, Plessy C, Irvine KM, Schroder K, Cloonan N, Steptoe AL, Lassmann T, et al. The regulated retrotransposon transcriptome of mammalian cells. Nat Genet. 2009;41(5):563-71.
74. Roy AM, West NC, Rao A, Adhikari P, Alemán C, Barnes AP, Deininger PL. Upstream flanking sequences and transcription of SINEs1. J Mol Biol. 2000;302(1):17-25.
75. Deininger P. Alu elements: know the SINEs. Genome Biol. 2011;12(12):1-12.
76. Bejerano G, Lowe CB, Ahituv N, King B, Siepel A, Salama SR, Rubin EM, James Kent W, Haussler D. A distal enhancer and an ultraconserved exon are derived from a novel retroposon. Nature. 2006;441(7089):87-90.
77. Lowe CB, Bejerano G, Haussler D. Thousands of human mobile element fragments undergo strong purifying selection near developmental genes. Proc Natl Acad Sci. 2007;104(19):8005-10.
78. Sasaki T, Nishihara H, Hirakawa M, Fujimura K, Tanaka M, Kokubo N, Kimura-Yoshida C, Matsuo I, Sumiyama K, Saitou N, et al. Possible involvement of SINEs in mammalian-specific brain formation. Proc Natl Acad Sci. 2008;105(11):4220-5.
79. Jjingo D, Conley AB, Wang J, Mariño-Ramírez L, Lunyak VV, Jordan IK: Mammalian-wide interspersed repeat (MIR)-derived enhancers and the regulation of human gene expression. Mobile DNA 2014, 5:14-14
80. Lynch VJ, Leclerc RD, May G, Wagner GP. Transposon-mediated rewiring of gene regulatory networks contributed to the evolution of pregnancy in mammals. Nat Genet. 2011;43(11):1154-9.
81. Lynch Vincent J, Nnamani Mauris C, Kapusta A, Brayer K, Plaza Silvia L, Mazur Erik C, Emera D, Sheikh Shehzad Z, Grützner F, Bauersachs S, et al. Ancient Transposable Elements Transformed the Uterine Regulatory Landscape and Transcriptome during the Evolution of Mammalian Pregnancy. Cell Rep. 2015;10(4):551-61.
82. Sinzelle L, Izsvak Z, Ivics Z. Molecular domestication of transposable elements: From detrimental parasites to useful host genes. Cell Mol Life Sci. 2009;66(6):1073-93.
83. Bowen NJ, Jordan IK. Transposable elements and the evolution of eukaryotic complexity. Curr Issues Mol Biol. 2002;4(3):65-76.
84. Dupressoir A, Lavialle C, Heidmann T. From ancestral infectious retroviruses to bona fide cellular genes: Role of the captured syncytins in placentation. Placenta. 2012;33(9):663-71.
85. Wolf D, Goff SP. Host Restriction Factors Blocking Retroviral Replication. Annu Rev Genet. 2008;42(1):143-63.
86. Friedli M, Turelli P, Kapopoulou A, Rauwel B, Castro-Diaz N, Rowe HM, Ecco G, Unzu C, Planet E, Lombardo A, et al. Loss of transcriptional control over endogenous retroelements during reprogramming to pluripotency. Genome Res. 2014;24(8):1251-9.
87. Jacobs FMJ, Greenberg D, Nguyen N, Haeussler M, Ewing AD, Katzman S, Paten B, Salama SR, Haussler D. An evolutionary arms race between KRAB zinc-finger genes ZNF91/93 and SVA/L1 retrotransposons. Nature. 2014;516(7530):242-5.
88. Wolf G, Greenberg D, Macfarlan T. Spotting the enemy within: Targeted silencing of foreign DNA in mammalian genomes by the Kruppel-associated box zinc finger protein family. Mob DNA. 2015;6(1):17.
89. Rowe HM, Trono D. Dynamic control of endogenous retroviruses during development. Virology. 2011;411(2):273-87.
90. Leung DC, Lorincz MC. Silencing of endogenous retroviruses: when and why do histone marks predominate? Trends Biochem Sci. 2012;37(4):127-33.
91. Liu S, Brind'Amour J, Karimi MM, Shirane K, Bogutz A, Lefebvre L, Sasaki H, Shinkai Y, Lorincz MC. Setdb1 is required for germline development and silencing of H3K9me3-marked endogenous retroviruses in primordial germ cells. Genes Dev. 2014;28(18):2041-55.
92. Yang F, Wang PJ: Multiple LINEs of retrotransposon silencing mechanisms in the mammalian germline. Semin Cell Dev Biol 2016, in press.
93. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726-34.
94. Timp W, Feinberg AP. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer. 2013;13(7):497-510.
95. Berdasco M, Esteller M. Aberrant Epigenetic Landscape in Cancer: How Cellular Identity Goes Awry. Dev Cell. 2010;19(5):698-711.
96. Skulte KA, Phan L, Clark SJ, Taberlay PC. Chromatin remodeler mutations in human cancers: epigenetic implications. Epigenomics. 2014;6(4):397-414.
97. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012;482(7384):226-31.
98. Shen H, Laird PW. Interplay between the Cancer Genome and Epigenome. Cell. 2013;153(1):38-55.
99. Nephew KP, Huang TH-M. Epigenetic gene silencing in cancer initiation and progression. Cancer Lett. 2003;190(2):125-33.
100. Kazanets A, Shorstova T, Hilmi K, Marques M, Witcher M. Epigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2016;1865(2):275-88.
101. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene. 2002;21(35):5400-13.
102. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol. 2005;83(3):296-321.
103. De Smet C, Loriot A. DNA hypomethylation in cancer: Epigenetic scars of a neoplastic journey. Epigenetics. 2010;5(3):206-13.
104. Ross JP, Rand KN, Molloy PL. Hypomethylation of repeated DNA sequences in cancer. Epigenomics. 2010;2(2):245-69.
105. Szpakowski S, Sun X, Lage JM, Dyer A, Rubinstein J, Kowalski D, Sasaki C, Costa J, Lizardi PM. Loss of epigenetic silencing in tumors preferentially affects primate-specific retroelements. Gene. 2009;448(2):151-67.
106. Barchitta M, Quattrocchi A, Maugeri A, Vinciguerra M, Agodi A. LINE-1 Hypomethylation in Blood and Tissue Samples as an Epigenetic Marker for Cancer Risk: A Systematic Review and Meta-Analysis. PLoS One. 2014;9(10):e109478.
107. Romanish MT, Cohen CJ, Mager DL. Potential mechanisms of endogenous retroviral-mediated genomic instability in human cancer. Semin Cancer Biol. 2010;20(4):246-53.
108. Piskareva O, Lackington W, Lemass D, Hendrick C, Doolan P, Barron N. The human L1 element: a potential biomarker in cancer prognosis, current status and future directions. Curr Mol Med. 2011;11(4):286-303.
109. Pérot P, Mullins CS, Naville M, Bressan C, Hühns M, Gock M, Kühn F, Volff J-N, Trillet-Lenoir V, Linnebacher M, et al. Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget. 2015;6(37):40095-111.
110. Haupt S, Tisdale M, Vincendeau M, Clements MA, Gauthier DT, Lance R, Semmes OJ, Turqueti-Neves A, Noessner E, Leib-Mösch C, et al. Human endogenous retrovirus transcription profiles of the kidney and kidney-derived cell lines. J Gen Virol. 2011;92(10):2356-66.
111. Gosenca D, Gabriel U, Steidler A, Mayer J, Diem O, Erben P, Fabarius A, Leib-Mˆsch C, Hofmann W-K, Seifarth W. HERV-E-Mediated Modulation of PLA2G4A Transcription in Urothelial Carcinoma. PLoS One. 2012;7(11):e49341.
112. Haase K, Mosch A, Frishman D. Differential expression analysis of human endogenous retroviruses based on ENCODE RNA-seq data. BMC Med Genet. 2015;8(1):71.
113. Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, Lenze D, Kochert K, Bouhlel MA, Richter J, Soler E, et al. Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med. 2010;16(5):571-9.
114. Bao W, Kojima KK, Kohany O. Repbase Update, a database of repetitive elements in eukaryotic genomes. Mob DNA. 2015;6(1):1-6.
115. Steidl C, Diepstra A, Lee T, Chan FC, Farinha P, Tan K, Telenius A, Barclay L, Shah SP, Connors JM, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120(17):3530-40.
116. Martín-Moreno AM, Roncador G, Maestre L, Mata E, Jiménez S, Martínez-Torrecuadrada JL, Reyes-García AI, Rubio C, Tomás JF, Estévez M, et al. CSF1R Protein Expression in Reactive Lymphoid Tissues and Lymphoma: Its Relevance in Classical Hodgkin Lymphoma. PLoS One. 2015;10(6):e0125203.
117. Babaian A, Romanish MT, Gagnier L, Kuo LY, Karimi MM, Steidl C, Mager DL. Onco-exaptation of an endogenous retroviral LTR drives IRF5 expression in Hodgkin lymphoma. Oncogene. 2016;35(19):2542-6.
118. Clark DN, Read RD, Mayhew V, Petersen SC, Argueta LB, Stutz LA, Till RE, Bergsten SM, Robinson BS, Baumann DG, et al. Four Promoters of IRF5 Respond Distinctly to Stimuli and are Affected by Autoimmune-Risk Polymorphisms. Front Immunol. 2013;4:360.
119. Kreher S, Bouhlel MA, Cauchy P, Lamprecht B, Li S, Grau M, Hummel F, Köchert K, Anagnostopoulos I, Jöhrens K, et al. Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma. Proc Natl Acad Sci. 2014;111(42):E4513-22.
120. Mancl ME, Hu G, Sangster-Guity N, Olshalsky SL, Hoops K, Fitzgerald-Bocarsly P, Pitha PM, Pinder K, Barnes BJ. Two Discrete Promoters Regulate the Alternatively Spliced Human Interferon Regulatory Factor-5 Isoforms: Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem. 2005;280(22):21078-90.
121. Introna M, Luchetti M, Castellano M, Arsura M, Golay J. The myb oncogene family of transcription factors: potent regulators of hematopoietic cell proliferation and differentiation. Semin Cancer Biol. 1994;5(2):113-24.
122. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. Nat Rev Cancer. 2008;8(7):523-34.
123. Wolff EM, Byun H-M, Han HF, Sharma S, Nichols PW, Siegmund KD, Yang AS, Jones PA, Liang G. Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer. PLoS Genet. 2010;6(4):e1000917.
124. Weber B, Kimhi S, Howard G, Eden A, Lyko F. Demethylation of a LINE-1 antisense promoter in the cMet locus impairs Met signalling through induction of illegitimate transcription. Oncogene. 2010;29(43):5775-84.
125. Hur K, Cejas P, Feliu J, Moreno-Rubio J, Burgos E, Boland CR, Goel A. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut. 2014;63(4):635-46.
126. Gao H, Guan M, Sun Z, Bai C. High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis. Tumor Biol. 2015;36(2):515-20.
127. Mariño-Enríquez A, Dal Cin P. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics. 2013;206(11):357-73.
128. Fantom-Consortium. A promoter-level mammalian expression atlas. Nature. 2014;507(7493):462-70.
129. Scarfò I, Pellegrino E, Mereu E, Kwee I, Agnelli L, Bergaggio E, Garaffo G, Vitale N, Caputo M, Machiorlatti R, et al. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. Blood. 2016;127(2):221-32.
130. Arteaga Carlos L, Engelman Jeffrey A. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell. 2014;25(3):282-303.
131. Obaidat A, Roth M, Hagenbuch B. The Expression and Function of Organic Anion Transporting Polypeptides in Normal Tissues and in Cancer. Annu Rev Pharmacol Toxicol. 2012;52(1):135-51.
132. Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, et al. Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. Cancer Res. 2008;68(24):10315-23.
133. Nagai M, Furihata T, Matsumoto S, Ishii S, Motohashi S, Yoshino I, Ugajin M, Miyajima A, Matsumoto S, Chiba K. Identification of a new organic anion transporting polypeptide 1B3 mRNA isoform primarily expressed in human cancerous tissues and cells. Biochem Biophys Res Commun. 2012;418(4):818-23.
134. Imai S, Kikuchi R, Tsuruya Y, Naoi S, Nishida S, Kusuhara H, Sugiyama Y. Epigenetic Regulation of Organic Anion Transporting Polypeptide 1B3 in Cancer Cell Lines. Pharm Res. 2013;30(11):2880-90.
135. Liang Q, Xu Z, Xu R, Wu L, Zheng S. Expression Patterns of Non-Coding Spliced Transcripts from Human Endogenous Retrovirus HERV-H Elements in Colon Cancer. PLoS One. 2012;7(1):e29950.
136. Teft WA, Welch S, Lenehan J, Parfitt J, Choi YH, Winquist E, Kim RB. OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. Br J Cancer. 2015;112(5):857-65.
137. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298-303.
138. Lock FE, Rebollo R, Miceli-Royer K, Gagnier L, Kuah S, Babaian A, Sistiaga-Poveda M, Lai CB, Nemirovsky O, Serrano I, et al. Distinct isoform of FABP7 revealed by screening for retroelement-activated genes in diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2014;111(34):E3534-43.
139. Thumser AE, Moore JB, Plant NJ. Fatty acid binding proteins: tissue-specific functions in health and disease. Curr Opin Clin Nutr Metab Care. 2014;17(2):124-9.
140. Liu R-Z, Graham K, Glubrecht DD, Lai R, Mackey JR, Godbout R. A fatty acid-binding protein 7/RXRβ pathway enhances survival and proliferation in triple-negative breast cancer. J Pathol. 2012;228(3):310-21.
141. Kapusta A, Kronenberg Z, Lynch VJ, Zhuo X, Ramsay L, Bourque G, Yandell M, Feschotte C. Transposable Elements Are Major Contributors to the Origin, Diversification, and Regulation of Vertebrate Long Noncoding RNAs. PLoS Genet. 2013;9(4):e1003470.
142. St Laurent G, Shtokalo D, Dong B, Tackett M, Fan X, Lazorthes S, Nicolas E, Sang N, Triche T, McCaffrey T, et al. VlincRNAs controlled by retroviral elements are a hallmark of pluripotency and cancer. Genome Biol. 2013;14(7):R73.
143. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet. 2013;45(11):1392-8.
144. Masliah-Planchon J, Bièche I, Guinebretière J-M, Bourdeaut F, Delattre O. SWI/SNF Chromatin Remodeling and Human Malignancies. Ann Rev Pathol Mech Dis. 2015;10(1):145-71.
145. Loewer S, Cabili MN, Guttman M, Loh Y-H, Thomas K, Park IH, Garber M, Curran M, Onder T, Agarwal S, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010;42(12):1113-7.
146. Wang Y, Xu Z, Jiang J, Xu C, Kang J, Xiao L, Wu M, Xiong J, Guo X, Liu H. Endogenous miRNA sponge lincRNA-RoR regulates Oct4, Nanog, and Sox2 in human embryonic stem cell self-renewal. Dev Cell. 2013;25(1):69-80.
147. Eades G, Wolfson B, Zhang Y, Li Q, Yao Y, Zhou Q. lincRNA-RoR and miR-145 Regulate Invasion in Triple-Negative Breast Cancer via Targeting ARF6. Mol Cancer Res. 2015;13(2):330-8.
148. Gao S, Wang P, Hua Y, Xi H, Meng Z, Liu T, Chen Z, Liu L. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget. 2016;7(2):1608-18.
149. Zhou P, Sun L, Liu D, Liu C, Sun L. Long Non-Coding RNA lincRNA-ROR Promotes the Progression of Colon Cancer and Holds Prognostic Value by Associating with miR-145. Pathol Oncol Res. 2016;22(4):733-40.
150. Fan J, Xing Y, Wen X, Jia R, Ni H, He J, Ding X, Pan H, Qian G, Ge S, et al. Long non-coding RNA ROR decoys gene-specific histone methylation to promote tumorigenesis. Genome Biol. 2015;16(1):139.
151. Huang J, Zhang A, Ho T-T, Zhang Z, Zhou N, Ding X, Zhang X, Xu M, Mo Y-Y. Linc-RoR promotes c-Myc expression through hnRNP I and AUF1. Nucleic Acids Res. 2016;44(7):3059-69.
152. Rangel LBA, Sherman-Baust CA, Wernyj RP, Schwartz DR, Cho KR, Morin PJ. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene. 2003;22(46):7225-32.
153. Adams Brian D, Kasinski Andrea L, Slack Frank J. Aberrant Regulation and Function of MicroRNAs in Cancer. Curr Biol. 2014;24(16):R762-76.
154. Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, Liu Y, Ou J, Wang D, Yao L, et al. LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet. 2015;24(3):841-52.
155. Yang F, Lyu S, Dong S, Liu Y, Zhang X, Wang O. Expression profile analysis of long noncoding RNA in HER-2-enriched subtype breast cancer by next-generation sequencing and bioinformatics. OncoTargets Ther. 2016;9:761-72.
156. Zeng Z, Bo H, Gong Z, Lian Y, Li X, Li X, Zhang W, Deng H, Zhou M, Peng S, et al. AFAP1-AS1, a long noncoding RNA upregulated in lung cancer and promotes invasion and metastasis. Tumor Biol. 2016;37(1):729-37.
157. Deng J, Liang Y, Liu C, He S, Wang S. The up-regulation of long non-coding RNA AFAP1-AS1 is associated with the poor prognosis of NSCLC patients. Biomed Pharmacother. 2015;75:8-11.
158. Wu W, Bhagat TD, Yang X, Song JH, Cheng Y, Agarwal R, Abraham JM, Ibrahim S, Bartenstein M, Hussain Z, et al. Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma. Gastroenterology. 2013;144(5):956-66. e954.
159. Zhang J-Y, Weng M-Z, Song F-B, Xu Y-G, Liu Q, Wu J-Y, Qin J, Jin T, Xu J-M. Long noncoding RNA AFAP1-AS1 indicates a poor prognosis of hepatocellular carcinoma and promotes cell proliferation and invasion via upregulation of the RhoA/Rac2 signaling. Int J Oncol. 2016;48:1590.
160. Guil S, Esteller M. Cis-acting noncoding RNAs: friends and foes. Nat Struct Mol Biol. 2012;19(11):1068-75.
161. Leucci E, Vendramin R, Spinazzi M, Laurette P, Fiers M, Wouters J, Radaelli E, Eyckerman S, Leonelli C, Vanderheyden K, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531(7595):518-22.
162. Harris ML, Baxter LL, Loftus SK, Pavan WJ. Sox proteins in melanocyte development and melanoma. Pigment Cell Melanoma Res. 2010;23(4):496-513.
163. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, et al. Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. Gastroenterology. 2007;132(1):330-42.
164. Li C, Chen J, Zhang K, Feng B, Wang R, Chen L. Progress and Prospects of Long Noncoding RNAs (lncRNAs) in Hepatocellular Carcinoma. Cell Physiol Biochem. 2015;36(2):423-34.
165. Wang X-S, Zhang Z, Wang H-C, Cai J-L, Xu Q-W, Li M-Q, Chen Y-C, Qian X-P, Lu T-J, Yu L-Z, et al. Rapid Identification of UCA1 as a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma. Clin Cancer Res. 2006;12(16):4851-8.
166. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett. 2008;582(13):1919-27.
167. Xue M, Chen W, Li X. Urothelial cancer associated 1: a long noncoding RNA with a crucial role in cancer. J Cancer Res Clin Oncol. 2016;142(7):1407-19.
168. Hu J-J, Song W, Zhang S-D, Shen X-H, Qiu X-M, Wu H-Z, Gong P-H, Lu S, Zhao Z-J, He M-L, et al. HBx-upregulated lncRNA UCA1 promotes cell growth and tumorigenesis by recruiting EZH2 and repressing p27Kip1/CDK2 signaling. Sci Rep. 2016;6:23521.
169. Flockhart RJ, Webster DE, Qu K, Mascarenhas N, Kovalski J, Kretz M, Khavari PA. BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration. Genome Res. 2012;22(6):1006-14.
170. Guo Q, Zhao YAN, Chen J, Hu JUN, Wang S, Zhang D, Sun Y. BRAF-activated long non-coding RNA contributes to colorectal cancer migration by inducing epithelial-mesenchymal transition. Oncol Lett. 2014;8(2):869-75.
171. Wang Y, Guo Q, Zhao YAN, Chen J, Wang S, Hu JUN, Sun Y. BRAF-activated long non-coding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma. Oncol Lett. 2014;8(5):1947-52.
172. Cruickshanks HA, Vafadar-Isfahani N, Dunican DS, Lee A, Sproul D, Lund JN, Meehan RR, Tufarelli C. Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer. Nucleic Acids Res. 2013;41(14):6857-69.
173. Cruickshanks HA, Tufarelli C. Isolation of cancer-specific chimeric transcripts induced by hypomethylation of the LINE-1 antisense promoter. Genomics. 2009;94(6):397-406.
174. Nigro CL, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, et al. Methylated Tissue Factor Pathway Inhibitor 2 (TFPI2) DNA in Serum Is a Biomarker of Metastatic Melanoma. J Investig Dermatol. 2013;133(5):1278-85.
175. Gibb E, Warren R, Wilson G, Brown S, Robertson G, Morin G, Holt R. Activation of an endogenous retrovirus-associated long non-coding RNA in human adenocarcinoma. Genome Med. 2015;7(1):22.
176. Tomczak K, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol. 2015;19(1A):A68-77.
177. Hashimoto K, Suzuki AM, Dos Santos A, Desterke C, Collino A, Ghisletti S, Braun E, Bonetti A, Fort A, Qin X-Y, et al. CAGE profiling of ncRNAs in hepatocellular carcinoma reveals widespread activation of retroviral LTR promoters in virus-induced tumors. Genome Res. 2015;25(12):1812-24.
178. Lania L, Di Cristofano A, Strazzullo M, Pengue G, Majello B, La Mantia G. Structural and functional organization of the human endogenous retroviral ERV9 sequences. Virology. 1992;191(1):464-8.
179. Santoni F, Guerra J, Luban J. HERV-H RNA is abundant in human embryonic stem cells and a precise marker for pluripotency. Retrovirology. 2012;9(1):111.
180. Ohnuki M, Tanabe K, Sutou K, Teramoto I, Sawamura Y, Narita M, Nakamura M, Tokunaga Y, Nakamura M, Watanabe A, et al. Dynamic regulation of human endogenous retroviruses mediates factor-induced reprogramming and differentiation potential. Proc Natl Acad Sci. 2014;111(34):12426-31.
181. Fuchs N, Loewer S, Daley G, Izsvak Z, Lower J, Lower R. Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology. 2013;10(1):115.
182. Grow EJ, Flynn RA, Chavez SL, Bayless NL, Wossidlo M, Wesche DJ, Martin L, Ware CB, Blish CA, Chang HY, et al. Intrinsic retroviral reactivation in human preimplantation embryos and pluripotent cells. Nature. 2015;522(7555):221-5.
183. Göke J, Lu X, Chan Y-S, Ng H-H, Ly L-H, Sachs F, Szczerbinska I. Dynamic Transcription of Distinct Classes of Endogenous Retroviral Elements Marks Specific Populations of Early Human Embryonic Cells. Cell Stem Cell. 2015;16(2):135-41.
184. Bannert N, Kurth R. Retroelements and the human genome: new perspectives on an old relation. Proc Natl Acad Sci U S A. 2004;101 Suppl 2:14572-9.
185. Li W, Lee M-H, Henderson L, Tyagi R, Bachani M, Steiner J, Campanac E, Hoffman DA, von Geldern G, Johnson K, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015;7(307):307ra153. 307ra153.
186. Costas J, Naveira H. Evolutionary History of the Human Endogenous Retrovirus Family ERV9. Mol Biol Evol. 2000;17(2):320-30.
187. Mager DL, Medstrand P. Retroviral Repeat Sequences. In: eLS. edn. Hoboken: Wiley; 2005.
188. Di Cristofano A, Strazullo M, Longo L, La Mantia G. Characterization and genomic mapping of the ZNF80 locus: Expression of this zinc-finger gene is driven by a solitary LTR of ERV9 endogenous retroviral family. Nucleic Acids Res. 1995;23:2823.
189. Chen H-J, Carr K, Jerome RE, Edenberg HJ. A Retroviral Repetitive Element Confers Tissue-Specificity to the Human Alcohol Dehydrogenase 1C (ADH1C) Gene. DNA Cell Biol. 2002;21(11):793-801.
190. Beyer U, Moll-Rocek J, Moll UM, Dobbelstein M. Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc Natl Acad Sci U S A. 2011;108(9):3624-9.
191. Pi W, Zhu X, Wu M, Wang Y, Fulzele S, Eroglu A, Ling J, Tuan D. Long-range function of an intergenic retrotransposon. Proc Natl Acad Sci U S A. 2010;107(29):12992-7.
192. Sokol M, Jessen KM, Pedersen FS. Human endogenous retroviruses sustain complex and cooperative regulation of gene-containing loci and unannotated megabase-sized regions. Retrovirology. 2015;12:32.
193. Beyer U, Kronung SK, Leha A, Walter L, Dobbelstein M. Comprehensive identification of genes driven by ERV9-LTRs reveals TNFRSF10B as a re-activatable mediator of testicular cancer cell death. Cell Death Differ. 2016;23:64-75.
194. Krönung SK, Beyer U, Chiaramonte ML, Dolfini D, Mantovani R, Dobbelstein M. LTR12 promoter activation in a broad range of human tumor cells by HDAC inhibition. Oncotarget. 2016;7(23):33484-497.
195. Xu L, Elkahloun AG, Candotti F, Grajkowski A, Beaucage SL, Petricoin EF, Calvert V, Juhl H, Mills F, Mason K, et al. A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest. J Virol. 2013;87(1):25-36.
196. Yu X, Zhu X, Pi W, Ling J, Ko L, Takeda Y, Tuan D. The Long Terminal Repeat (LTR) of ERV-9 Human Endogenous Retrovirus Binds to NF-Y in the Assembly of an Active LTR Enhancer Complex NF-Y/MZF1/GATA-2. J Biol Chem. 2005;280(42):35184-94.
197. Gasparini P, Sozzi G, Pierotti MA. The role of chromosomal alterations in human cancer development. J Cell Biochem. 2007;102(2):320-31.
198. Oh S, Shin S, Janknecht R. ETV1, 4 and 5: An oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta. 2012;1826(1):1-12.
199. Tomlins SA, Laxman B, Dhanasekaran SM, Helgeson BE, Cao X, Morris DS, Menon A, Jing X, Cao Q, Han B, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature. 2007;448(7153):595-9.
200. Goering W, Schmitt K, Dostert M, Schaal H, Deenen R, Mayer J, Schulz WA. Human endogenous retrovirus HERV-K(HML-2) activity in prostate cancer is dominated by a few loci. Prostate. 2015;75(16):1958-71.
201. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotech. 2011;29(8):742-9.
202. Kumar KR, Chen W, Koduru PR, Luu HS. Myeloid and Lymphoid Neoplasm With Abnormalities of FGFR1 Presenting With Trilineage Blasts and RUNX1 Rearrangement. Am J Clin Pathol. 2015;143(5):738-48.
203. Guasch G, Popovici C, Mugneret F, Chaffanet M, Pontarotti P, Birnbaum D, Pébusque M-J. Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3). Blood. 2002;101(1):286-8.
204. Lamprecht B, Bonifer C, Mathas S. Repeat element-driven activation of proto-oncogenes in human malignancies. Cell Cycle. 2010;9(21):4276-81.
205. Böhne A, Brunet F, Galiana-Arnoux D, Schultheis C, Volff J-N. Transposable elements as drivers of genomic and biological diversity in vertebrates. Chromosom Res. 2008;16(1):203-15.
206. Rebollo R, Horard B, Hubert B, Vieira C. Jumping genes and epigenetics: Towards new species. Gene. 2010;454(1-2):1-7.
207. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG, Wen B, Wu H, Liu Y, Diep D, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet. 2011;43(8):768-75.
208. Landau Dan A, Clement K, Ziller Michael J, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, et al. Locally Disordered Methylation Forms the Basis of Intratumor Methylome Variation in Chronic Lymphocytic Leukemia. Cancer Cell. 2014;26(6):813-25.
209. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nat Med. 2016;22(7):792-9.
210. Mazor T, Pankov A, Song Jun S, Costello Joseph F. Intratumoral Heterogeneity of the Epigenome. Cancer Cell. 2016;29(4):440-51.
211. Hanahan D, Weinberg Robert A. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646-74.
212. Brock A, Chang H, Huang S. Non-genetic heterogeneity - a mutation-independent driving force for the somatic evolution of tumours. Nat Rev Genet. 2009;10(5):336-42.
213. Werfel J, Krause S, Bischof AG, Mannix RJ, Tobin H, Bar-Yam Y, Bellin RM, Ingber DE. How Changes in Extracellular Matrix Mechanics and Gene Expression Variability Might Combine to Drive Cancer Progression. PLoS One. 2013;8(10):e76122.
214. Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, Huang S. Non-Darwinian dynamics in therapy-induced cancer drug resistance. Nat Commun. 2013;4:2467.
215. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer. 2012;12(5):323-34.
216. Bashtrykov P, Jankevicius G, Smarandache A, Jurkowska Renata Z, Ragozin S, Jeltsch A. Specificity of Dnmt1 for Methylation of Hemimethylated CpG Sites Resides in Its Catalytic Domain. Chem Biol. 2012;19(5):572-8.
217. Lavie L, Kitova M, Maldener E, Meese E, Mayer J. CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol. 2005;79(2):876-83.
218. van de Lagemaat LN, Landry J-R, Mager DL, Medstrand P. Transposable elements in mammals promote regulatory variation and diversification of genes with specialized functions. Trends Genet. 2003;19(10):530-6.
219. Simons C, Pheasant M, Makunin IV, Mattick JS. Transposon-free regions in mammalian genomes. Genome Res. 2006;16(2):164-72.
220. Mortada H, Vieira C, Lerat E. Genes Devoid of Full-Length Transposable Element Insertions are Involved in Development and in the Regulation of Transcription in Human and Closely Related Species. J Mol Evol. 2010;71(3):180-91.
221. Sorek R, Ast G, Graur D. Alu-Containing Exons are Alternatively Spliced. Genome Res. 2002;12(7):1060-7.
222. Vorechovsky I. Transposable elements in disease-associated cryptic exons. Hum Genet. 2010;127(2):135-54.
223. Darby MM, Leek JT, Langmead B, Yolken RH, Sabunciyan S: Widespread splicing of repetitive element loci into coding regions of gene transcripts. Hum Mol Gen 2016, in press.
224. Lev Maor G, Yearim A, Ast G. The alternative role of DNA methylation in splicing regulation. Trends Genet. 2015;31(5):274-80.
225. Laurette P, Strub T, Koludrovic D, Keime C, Le Gras S, Seberg H, Van Otterloo E, Imrichova H, Siddaway R, Aerts S, et al. Transcription factor MITF and remodeller BRG1 define chromatin organisation at regulatory elements in melanoma cells. eLife. 2015;4:e06857.